# ER+/PR- Receptor Status
### Part one: Plain-language overview
Start here if you want the short version first.
This first section explains what PR-negative status can mean in practical terms.
It focuses on treatment fit, risk, and the questions worth asking next.
#### Who is this for?
This is for anyone with ER-positive breast cancer who has seen `PR negative` or `PR positive` on their pathology report and wants to understand what that actually means for treatment and future planning.
#### First: what are ER and PR?
**ER** stands for **estrogen receptor**.
**PR** stands for **progesterone receptor**.
When you are diagnosed with breast cancer, your tumour is tested to see whether these receptors are present.
If **ER** is positive, the cancer is being driven by oestrogen signals.
If **PR** is positive, it means the progesterone receptor is also present, which usually suggests the hormone-signalling system is still working in a more regulated way.
Your report includes both results, and the **PR** result often matters more than many patients realise.
Think of ER and PR like a two-switch electrical system.
ER being positive means the power is on.
PR being positive means the second switch is also working.
That second switch acts like a regulator that keeps things more controlled and predictable.
When PR is off, the cancer is still oestrogen-driven, but it is missing that regulating layer.
That can make it behave differently.
#### What does PR negative actually mean in practice?
If your report says **ER+/PR−**, here is what that means in plain terms:
* Your cancer is still hormone-driven. It is not the same as triple-negative breast cancer.
* It tends to be more unpredictable and a bit more aggressive than ER+/PR+ cancer.
* Endocrine therapies still work, but not always as reliably, and the choice of therapy matters more.
* Recurrence risk is somewhat higher than in ER+/PR+ disease, but treatment can reduce that risk substantially.
* Resistance to hormone therapy is more likely over time, so active monitoring matters.
#### Does this mean tamoxifen will not work for me?
Not necessarily.
This is where PR status becomes especially important for treatment choices.
Research suggests that ER+/PR− tumours respond about **30–40% less well to tamoxifen** than ER+/PR+ tumours.
Tamoxifen is a **SERM**.
It sits in the oestrogen receptor and blocks it, but it does not fully switch the receptor off.
In PR− cancers, other pathways may also bypass that block.
**Aromatase inhibitors** — letrozole, anastrozole, and exemestane — work differently and are often a better fit for PR− disease.
They may help because:
* They cut off the oestrogen supply far more completely.
* They may create a more favourable internal hormone balance inside the tumour.
* They sidestep some of the bypass routes that can make tamoxifen less reliable in PR− cases.
If you are post-menopausal and ER+/PR−, an aromatase inhibitor is generally preferred over tamoxifen.
If you are already on tamoxifen and are PR−, it may be worth discussing an AI switch with your oncologist.
#### What is an ESR1 mutation and should I be worried?
This matters most in metastatic disease.
ESR1 is the gene that makes your oestrogen receptor.
Mutations in this gene can develop during hormone therapy, especially during aromatase inhibitor treatment.
They can make the receptor switch itself on permanently, even without oestrogen present.
When that happens, an aromatase inhibitor may stop working as well because there is less oestrogen left to suppress.
Key things to know:
* ESR1 mutations are rare at first diagnosis.
* They develop in about **20–40%** of patients with metastatic disease after time on aromatase inhibitors.
* They can now be detected with a blood test called a **liquid biopsy** or **ctDNA test**.
* ESR1 mutations do **not** mean treatment options have run out.
#### How do CDK4/6 inhibitors fit in?
This is the part that surprises many patients.
**CDK4/6 inhibitors** — ribociclib, palbociclib, and abemaciclib — work differently from hormone therapy.
Hormone therapy targets the oestrogen receptor near the top of the signalling chain.
Cancer cells can sometimes bypass that level.
That is one reason ESR1 mutations matter.
A CDK4/6 inhibitor works further downstream.
It blocks the machinery the cell needs before it can divide.
That means it can still help even when the receptor pathway has become less reliable.
What this means in practice:
* If you are PR− and high risk, adding a CDK4/6 inhibitor early gives a second line of defence.
* Five-year NATALEE data for ribociclib showed a **28% sustained reduction in recurrence risk**.
* If an ESR1 mutation appears, the usual next step is not to stop the CDK4/6 inhibitor. The endocrine partner may change instead.
#### Can PR status change over time?
Yes.
This is something many patients are never told.
A tumour may be ER+/PR+ at first diagnosis, then lose PR expression during hormonal therapy.
This can happen because:
1. Treatment suppresses the oestrogen signalling that normally helps drive PR production.
2. Under treatment pressure, PR-negative cell populations can survive and expand.
3. Growth factor pathways such as **HER2** and **EGFR** can become more active and suppress PR.
This is why repeat biopsy at recurrence or progression matters.
The tumour being treated later may not match the one biopsied at diagnosis.
#### Quick reference summary
If you are **ER+/PR+**:
* Full hormonal signalling is still intact.
* Prognosis is usually better within ER-positive disease.
* Ask about standard endocrine therapy, plus a CDK4/6 inhibitor if risk is high.
If you are **ER+/PR−**:
* The cancer is still hormone-driven, but less regulated.
* Resistance risk is higher.
* Ask about an aromatase inhibitor, CDK4/6 inhibitor use, and ESR1 liquid biopsy monitoring.
If you are **PR− and currently on tamoxifen**:
* You may not be getting the best endocrine fit.
* Ask whether an aromatase inhibitor would be more appropriate.
If you are **progressing on AI therapy**:
* An ESR1 mutation may be developing.
* Ask about ctDNA testing, fulvestrant, or a next-generation oral SERD.
If you were **PR+ at diagnosis** but are now being re-biopsied:
* PR status may have changed.
* Ask for full repeat receptor testing on the new sample.
#### The bottom line
Being **ER+/PR−** does not mean you are out of options.
Far from it.
It means the cancer needs a more tailored approach.
The good news is that treatment options have improved sharply.
An aromatase inhibitor plus a CDK4/6 inhibitor, with liquid-biopsy monitoring in the background, can protect at more than one level at once.
Understanding PR status is the first step in making sure the treatment plan matches the tumour biology.
Bring this page to your next oncology appointment.
The questions it raises are exactly the right ones to ask.
{% hint style="info" %}
This plain-language section sits above the deeper clinical report.
For referenced sources and a deeper grasp, continue below.
{% endhint %}
***
### Part two: Deep dive
This section goes deeper into the biology, treatment-response patterns, resistance mechanisms, and research behind ER-positive, PR-negative disease.
#### The Impact of Progesterone Receptor Status on Breast Cancer Biology and Treatment Efficacy
### Jump to
* [Overview](#overview)
* [Molecular Biology of PR Signalling](#molecular-biology-of-pr-signalling)
* [Mechanisms Underlying PR Loss](#mechanisms-underlying-pr-loss)
* [PR Status and Differential Response to Endocrine Therapies](#pr-status-and-differential-response-to-endocrine-therapies)
* [ESR1 Mutations: Their Connection to PR Loss and the CDK4/6 Inhibitor Solution](#esr1-mutations-their-connection-to-pr-loss-and-the-cdk46-inhibitor-solution)
* [ERα/ERβ Biology and Letrozole-Specific Advantages](#erαerβ-biology-and-letrozole-specific-advantages)
* [Prognostic Implications of PR Status](#prognostic-implications-of-pr-status)
* [Integrative and Epigenetic Strategies Targeting PR Loss](#integrative-and-epigenetic-strategies-targeting-pr-loss)
* [Emerging Research Directions](#emerging-research-directions)
* [Clinical Implications for ER+ Patient Subgroups](#clinical-implications-for-er-patient-subgroups)
* [References](#references)
### Overview
**Progesterone receptor (PR) status** is one of the most clinically consequential biomarkers in estrogen receptor-positive (ER+) breast cancer.
While ER positivity signals likely hormonal dependency, PR co-expression (or its absence) fundamentally shapes the biological character of a tumour, the reliability of endocrine therapy, and the risk of treatment resistance.
Approximately 12% of all breast cancers present as ER+/PR−, and this subgroup exhibits markedly distinct clinical behaviour — higher recurrence rates, more aggressive molecular profiles, and less predictable responses to the endocrine agents that anchor most ER+ treatment protocols.
This report synthesises the molecular basis of PR signalling, the mechanisms underlying PR loss, the distinct clinical consequences of PR-negative status including differential sensitivity to tamoxifen versus aromatase inhibitors, the interplay between PR loss and ESR1 mutations, the role of CDK4/6 inhibitors in overcoming ESR1-driven resistance, and integrative strategies that may target vulnerabilities unique to the ER+/PR− phenotype.
Emerging research — including updated clinical data through 2025 — substantially expands the picture beyond what was understood even five years ago.
***
### Molecular Biology of PR Signalling
#### The Two PR Isoforms and Their Roles
The progesterone receptor is encoded as two primary isoforms — PR-A (769 amino acids) and PR-B (933 amino acids) — transcribed from the same gene on chromosome 11q22–q23 via two distinct promoters.
In normal breast tissue, these isoforms are co-expressed in a 1:1 ratio, but in breast cancer this balance is frequently disrupted.
PR-B is the full-length isoform and serves as the predominant mediator of mitogenic progesterone signalling, while PR-A lacks the N-terminal 164 amino acids of PR-B and acts more as a transcriptional repressor of PR-B activity.
Research published in the Journal of the National Cancer Institute (2017) established that a high PR-A/PR-B ratio functions as both a prognostic and predictive factor for anti-progestin responsiveness, while a high PR-B proportion correlates with higher Ki-67 expression and worse prognosis.
A 2025 analysis published in Endocrinology further clarified that the two isoforms regulate distinct gene networks, with PR-B controlling expression of RANKL, Cyclin D1 (CCND1), and the proto-oncogene MYC, all of which are relevant to cell cycle progression and therapeutic responsiveness in ER+ cancer.
These findings reinforce the importance of measuring not merely PR presence or absence, but the isoform balance, to predict endocrine outcomes accurately.
#### PR as a Functional Readout of ER Signalling
PR expression is directly dependent on functional ER→transcription→PR promoter activation.
For this reason, PR serves as a surrogate marker for a competent, intact oestrogen signalling axis.
When PR is absent in the presence of ER positivity, this is a strong signal that the ER pathway itself is either dysregulated, bypassed, or that epigenetic silencing has interrupted downstream transcription.
A 2025 systematic review in Translational Oncology confirmed this principle, noting that ER+/PR− breast cancers exhibit lower PR mRNA at the transcriptional level, meaning loss occurs before translation even begins — and this transcriptional silencing is often the consequence of upstream signalling disruption rather than a simple protein-level issue.
#### ER/PR Crosstalk: A Dynamic Regulatory System
ER and PR engage in extensive reciprocal regulation rather than simply operating in parallel.
Mohammed et al. demonstrated in MCF-7 and T47D breast cancer cell models that co-stimulation with oestrogen caused PR to associate with chromatin-bound ER complexes, driving a significant reorganisation of ER genomic recruitment from classical oestrogen response elements (EREs) toward progesterone response elements (PREs).
This remodelling of the transcriptional landscape means that in PR+ tumours, progesterone stimulation can actually redirect ER-driven proliferative signals, functioning as a tumour-suppressive brake in some contexts.
Giulianelli and colleagues further showed that ER and PR co-bind at target gene promoters for genes including CCND1 and MYC, with the synthetic progestin MPA triggering rapid nuclear co-localisation of both receptors.
This ER/PR physical interaction helps explain why PR+ status is associated with a more organised, differentiated, and therapeutically tractable tumour phenotype.
In PR− tumours, this regulatory co-operation is absent.
The loss of PR-mediated chromatin reprogramming leaves ER-driven transcription unchecked, with consequences for proliferation, inflammatory signalling, and resistance to selective oestrogen receptor modulators (SERMs).
***
### Mechanisms Underlying PR Loss
#### Genetic Copy Number Loss
A 2025 review in Translational Oncology identified primary loss of PR gene copy number as one of the earliest and most prevalent mechanisms of PR negativity.
Using the TCGA cohort, Liu et al. found that ER+/PR− breast cancers exhibit significantly more copy number losses at the PR gene locus (11q22–q23) than ER+/PR+ tumours — with hemizygous or homozygous deletions occurring in 27.5% of ER+/PR− cases versus 17.5% in ER+/PR+ cases.
Loss of heterozygosity (LOH) at the PR locus on chromosome 11q23 has been documented in approximately 40% of primary breast cancers and is closely correlated with reduced PR protein expression.
#### Epigenetic Silencing via Promoter Methylation
Promoter methylation silences PR gene transcription in 21–40% of ER+/PR− breast cancers.
Methylation-mediated silencing recruits methyl-CpG binding proteins that associate with histone deacetylases (HDACs) and other chromatin-remodelling factors, resulting in transcriptional shutdown.
A study by Fiegl et al. confirmed that PR promoter methylation levels are significantly higher in ER+/PR− compared to ER+/PR+ tumours, and that both gene copy number loss and high promoter methylation operate independently yet cooperatively — together accounting for approximately 75% of ER+/PR− breast cancers.
Critically, PR expression has been restored in PR-negative cell lines following treatment with HDAC inhibitors and DNA methyltransferase inhibitors such as decitabine, opening a potential therapeutic window for re-sensitisation to endocrine therapy.
#### miRNA-Mediated Downregulation
Several oncogenic microRNAs disrupt ER-dependent signalling and directly suppress PR transcription.
miR-181a, miR-23a, and miR-26b all downregulate PR expression in ER-positive breast cancer.
Of particular importance, miR-129-2 — upregulated by progesterone in a negative feedback loop — has been shown in the TCGA cohort to correlate inversely with PR expression: patients with elevated miR-129-2 exhibit significantly reduced PR levels.
miR-129-2 inhibition restores PR expression in vitro, suggesting that this miRNA-driven silencing is functionally reversible and may represent a targetable mechanism.
#### Growth Factor Pathway-Mediated PR Loss
This mechanism carries the most direct therapeutic implications.
Growth factors including IGF, EGF, and their associated receptors (EGFR/HER2) activate the PI3K/AKT/mTOR pathway, which suppresses PR expression at the transcriptional level by blocking the AP-1 binding site in the PR gene promoter.
Increased HER2 or EGFR signalling is consistently found to correlate with ER+/PR− status, and multiple studies have confirmed that loss of PR in ER+ cancers occurs concomitantly with upregulation of ErbB/HER family kinases and RAS/PI3K pathways.
This explains why ER+/PR− tumours phenotypically resemble Luminal B or borderline HER2-enriched cancers despite technical ER positivity.
A 2020 study published in PMC confirmed that loss of PR is associated with distinct tyrosine kinase signatures — particularly upregulation of FGFR4, LCK, and enrichment of RAS, PI3K, and ErbB signalling — in ER+/HER2− breast cancer.
This supports the biological model in which growth factor pathway hyperactivation drives the cell into a state where PR expression becomes functionally redundant and is consequently silenced.
#### PR Loss During Endocrine Therapy
A major but underappreciated reality is that PR loss is not always a fixed primary tumour characteristic — it can be acquired as a direct consequence of treatment.
Continuous biopsy studies have revealed that while ER levels decline only modestly under endocrine therapy, PR levels drop far more sharply, with up to half of tumours completely losing PR expression when resistance to tamoxifen develops.
The mechanism involves: (1) ER pathway suppression eliminating the transcriptional input required to maintain PR expression; (2) selective outgrowth of PR− clones under therapeutic pressure; and (3) compensatory activation of growth factor pathways (EGFR/HER2) that independently suppress PR.
This means a tumour documented as ER+/PR+ at diagnosis may arrive at progression as functionally ER+/PR−, with all the associated consequences for subsequent endocrine therapy choices.
A 2025 study in Frontiers of Endocrinology noted that heterozygous PTEN deletion co-occurring with HER2 overexpression leads to significant Akt activation and PR loss, while ERα homodimers forming heterodimers with ERβ1 may also downregulate several ERα-dependent genes including PR — connecting acquired PR loss directly to the ERα/ERβ ratio shifts discussed below.
***
### PR Status and Differential Response to Endocrine Therapies
#### Tamoxifen: PR as a Determinant of Response
ER+/PR− tumours show 30–40% lower response rates to tamoxifen compared to ER+/PR+ tumours.
This occurs through several converging mechanisms.
PR negativity itself signals a dysfunctional ER axis, meaning tamoxifen has less effective ER machinery to modulate.
In addition, as described above, growth factor pathway activity — the primary molecular driver of PR loss — actively bypasses the ER signalling axis that tamoxifen targets: phosphorylation of ERα at Ser118 and Ser167 by MAPK and PI3K/AKT allows ligand-independent ER activation that is not blocked by SERM binding.
There is also an important isoform consideration.
Isoform-specific promoter methylation studies have shown that PRA methylation can raise the PRA/PRB ratio by selectively silencing PRA, increasing dominance of PRB.
Since PRB-induced target gene expression has been shown to enhance tamoxifen resistance, and since antiprogestins are more effective against PRA-predominant tumours, the methylation-driven shift in isoform ratio represents a mechanism specifically linking PR epigenetics to SERM failure.
#### Aromatase Inhibitors: A More Favourable Interaction with PR− Tumours
In contrast to tamoxifen, aromatase inhibitors (AIs) show a different relationship with PR status, and this distinction is clinically significant.
Molecular profiling studies (Nature Communications, 2023) have demonstrated that AI-resistant tumours are associated with ESR1 upregulation, decreased compositional heterogeneity, and MAPK/ERBB pathway enrichment — but PR− status, while predictive of a generally more aggressive phenotype, does not confer the same degree of SERM-type resistance to AIs that it does to tamoxifen.
AIs do not engage the ER directly; they reduce the ligand available to stimulate it.
This mechanism retains utility even when PR expression has been lost, provided residual ER function persists.
A key mechanistic distinction involves the ERα/ERβ ratio.
A 2009 study published in Anticancer Research (PMID 19528477) demonstrated that tamoxifen and antiestrogens downregulate ERβ expression, while aromatase inhibitors — specifically anastrozole and letrozole — upregulate ERβ relative to ERα, producing a lower ERα/ERβ ratio.
ERβ is broadly associated with anti-proliferative and pro-apoptotic effects in breast tissue.
ERβ expression is notably lower in breast cancer and lymph node metastasis compared to normal tissue, and its restoration correlates with improved prognosis.
A 2011 study confirmed that ERβ agonism combined with letrozole blocked growth of letrozole-resistant breast cancer tumours, with an observed increase in ERβ levels and diminished ERα/ERβ ratio in treated mice.
This ERβ-upregulating property of AIs represents a mechanistic advantage in ER+/PR− patients, where the ERα-dominant, growth factor-active transcriptional environment is precisely the context in which ERβ activity is most needed.
Letrozole achieves near-complete suppression of circulating oestrogen.
A landmark comparative pharmacology study (PMID 11821457) quantified that treatment with letrozole at 2.5 mg/day suppressed plasma estrone (E1) by 84.3%, estradiol (E2) by 87.8%, and estrone sulfate (E1S) by 98.0% — significantly exceeding anastrozole's suppression of 81.0%, 84.9%, and 93.5%, respectively (with E1S and E1 differences reaching statistical significance at p = 0.0037 and p = 0.019).
A subsequent 2008 Journal of Clinical Oncology study further confirmed that following letrozole, only 1 of 54 patients retained E2 levels ≥3 pmol/L, versus 20 of 54 on anastrozole.
This near-total estrogen deprivation may provide an additional advantage in ER+/PR− disease, where the residual ER-driven signalling is less well-regulated by PR-mediated counter-signalling and therefore more critically dependent on ligand availability.
Taken together, the evidence supports preferring aromatase inhibitors over tamoxifen specifically in the ER+/PR− setting, where tamoxifen's partial agonist activity and PR-bypass resistance mechanisms are more likely to be operative.
***
### ESR1 Mutations: Their Connection to PR Loss and the CDK4/6 Inhibitor Solution
#### ESR1 Mutations as Drivers of Acquired Endocrine Resistance
ESR1 mutations emerge in 20–40% of patients with hormone receptor-positive metastatic breast cancer who have received prior aromatase inhibitor therapy.
These mutations — most commonly at codons Y537 and D538 in the ligand-binding domain of the oestrogen receptor — confer constitutive, ligand-independent ER activity, allowing tumour cells to proliferate despite oestrogen suppression.
ESR1 mutations are rarely detected at primary diagnosis but emerge progressively under the selective pressure of AI-based therapy.
ESR1 mutations and PR loss are functionally related.
PR expression requires intact, transcriptionally active ERα signalling.
ESR1 mutations, while constitutively activating the receptor at the structural level, alter its transcriptional partner interactions and target gene repertoire — and this altered signalling may fail to maintain the transcriptional inputs that normally sustain PR expression.
A 2025 study in Nature Genomics identified a TP53-PIK3CA-ESR1 resistance signature as the dominant genomic hallmark of endocrine therapy resistance in ER/PR+/HER2− breast cancer, reinforcing that ESR1 mutation rarely acts in isolation but rather as part of a co-evolving resistance landscape.
Single-nucleus RNA sequencing at ESMO MAP 2024 further revealed that AI-resistant ER+ tumours show ESR1 upregulation alongside decreased compositional heterogeneity and enrichment in MAPK/ERBB pathway gene clusters — providing a transcriptomic signature of the PR-loss, growth factor-active state.
#### CDK4/6 Inhibitors: Overcoming ESR1-Dependent Resistance
A 2023 study published in Cancers (University of Pisa) provided direct clinical evidence that CDK4/6 inhibitors overcome ESR1-dependent endocrine resistance.
In 42 metastatic ER+ breast cancer patients — including both ESR1-mutant and wild-type — no statistically significant difference in progression-free survival was observed between ESR1-mutant and non-mutant patients when treated with CDK4/6 inhibitors plus endocrine therapy as first-line treatment (p = 0.29).
This means that the resistance to endocrine therapy driven by ESR1 mutations does not translate into resistance to the CDK4/6 inhibitor combination.
Multivariate analysis confirmed ESR1 mutations as independent predictors of shorter disease-free survival in the adjuvant setting, but this disadvantage was effectively negated by CDK4/6 inhibitor addition at the metastatic stage.
The mechanism by which CDK4/6 inhibitors bypass ESR1-driven resistance is dual.
First, CDK4/6 inhibitors directly target the cyclin D1-CDK4/6-retinoblastoma protein (Rb) axis downstream of hormone receptor signalling.
Even when oestrogen receptor signalling is constitutively active via ESR1 mutation, the subsequent cell cycle machinery — including cyclin D1 transcription and CDK4/6 activation — remains susceptible to pharmacological inhibition.
Second, CDK4/6 inhibitors retain synergy with residual ER signalling: studies confirm that they work in concert with whatever endocrine activity is present, rather than depending on a fully intact ER-to-PR signalling chain.
This makes them particularly well-suited to the ER+/PR− context, where the ER axis is dysfunctional but not silent.
The five-year NATALEE trial data for ribociclib (Kisqali), published in October 2025, demonstrated a sustained 28.4% reduction in recurrence risk (HR = 0.716; 95% CI 0.618–0.829) across the broadest population of HR+/HER2− early breast cancer patients, with invasive disease-free survival rates of 85.5% versus 81.0% for endocrine therapy alone — importantly maintaining benefit well beyond the completion of treatment.
This durability suggests that CDK4/6 inhibitor-mediated cell cycle suppression leaves a lasting imprint on tumour biology that persists after drug discontinuation, which has important implications for high-risk ER+/PR− patients where conventional endocrine therapy alone is unlikely to be sufficient.
#### The PADA-1 Trial and ESR1 Monitoring
The PADA-1 trial introduced the concept of ESR1 mutation monitoring via liquid biopsy to guide therapeutic switches in real time.
The trial demonstrated that upon detection of a rising ESR1 mutation in ctDNA during AI plus palbociclib therapy, switching the endocrine partner from AI to fulvestrant while continuing the CDK4/6 inhibitor doubled median progression-free survival.
This framework — treat to molecular signal, then adapt — is highly relevant in ER+/PR− disease where ESR1 mutations are more likely to emerge due to the greater reliance on AI-based suppression and the lower regulatory stability conferred by absent PR signalling.
***
### ERα/ERβ Biology and Letrozole-Specific Advantages
#### The ERα/ERβ Balance in Tumour Progression
Estrogen receptor beta (ERβ) was long viewed as an onlooker in breast cancer biology, but evidence increasingly positions it as a functionally important anti-proliferative counterweight to ERα.
ERα is the dominant proliferative driver in luminal breast cancer, while ERβ promotes cell death through non-genomic and pro-apoptotic pathways and is thought to act as a tumour suppressor.
ERβ mRNA is notably lower in breast cancer and lymph node metastasis tissues compared to normal and benign breast, and higher ERβ expression is associated with more favourable prognosis.
The ERα/ERβ ratio thus serves as a measure of the tumour's proliferative versus anti-proliferative hormonal balance.
#### Letrozole and AI-Mediated ERβ Upregulation
The 2009 Anticancer Research study (PMID 19528477) was particularly revealing on this point.
While the transition from normal breast to low-grade tumour is characterised by ERβ downregulation, treatment with third-generation AIs (anastrozole RQ = 1.23, p = 0.029; letrozole RQ = 1.38, p = 0.048) actively upregulates ERβ expression — in stark contrast to antiestrogens including tamoxifen, which downregulate it.
This represents a qualitative pharmacological difference between SERM and AI therapy, not merely a quantitative difference in oestrogen suppression.
In ER+/PR− tumours where ERα-driven transcriptional dysregulation is already problematic, the ERβ-upregulating property of letrozole may help restore a partially inhibitory hormonal balance that tamoxifen not only fails to create but may actively worsen.
This finding connects to the broader principle that AI-mediated oestrogen deprivation reshapes the intracellular receptor landscape in a way that tamoxifen does not, providing a biological rationale — beyond simple potency comparisons — for preferring AIs in PR-negative disease.
***
### Prognostic Implications of PR Status
#### Survival Outcomes
PR− status in ER+ breast cancer carries consistent prognostic weight across multiple large studies.
PR-positive tumours are associated with 10–15% higher 10-year survival rates independent of ER status.
A prospective cohort study (PMC 1851385) documented 5-year survival rates of 96% in PR+ versus significantly lower rates in PR−/HER2+ cohorts.
ER+/PR− status confers a 2.68-fold higher recurrence risk compared to ER+/PR+, and in lymph node analyses, ER+/PR− tumours show frequent co-occurrence with basal-like features, BRCA1 mutations, and elevated Ki-67 — all markers of a biologically aggressive phenotype that does not match the favourable forecast conventionally associated with ER positivity.
PR+ inhibits HER2/neu and EGFR overexpression and reduces basal-like markers, explaining the gradient of aggressiveness from PR+/ER+ (most organised, best prognosis) through PR−/ER+ (intermediate, resistance-prone) to triple-negative disease.
A 2023 single-centre prospective cohort study in PMC (PMC10341192) confirmed that PR expression level in ER+/HER2− young breast cancer predicts prognosis, with higher PR correlating with longer disease-free and overall survival — and identified that the subgroup with the lowest PR levels has outcomes that approach those of Luminal B disease despite nominal ER positivity.
#### Predictive Value for Chemotherapy
An important clinical nuance is that PR negativity, while a marker of poorer endocrine therapy response, is associated with higher initial sensitivity to chemotherapy.
PR− tumours typically exhibit higher mitotic rates and therefore greater response to anthracyclines, taxanes, and other cytotoxic agents in the neoadjuvant setting.
This is consistent with the observation that ER+/PR− cancers occupy a clinical middle ground: less well-managed by endocrine monotherapy, but more tractable with chemotherapy than their PR+ counterparts.
This distinction informs the practical treatment decision in neoadjuvant settings where pathologic complete response rates can be used to guide further management.
***
### Integrative and Epigenetic Strategies Targeting PR Loss
#### Restoring PR Expression via Epigenetic Reversal
Given that 75% of ER+/PR− tumours show evidence of PR gene copy number loss and/or promoter methylation, epigenetic strategies to restore PR expression represent a coherent biological target.
HDAC inhibitors and DNA methyltransferase inhibitors (including decitabine/5-azacytidine) have restored PR mRNA expression in PR-negative cell lines, and low-dose curcumin combined with decitabine has been shown to restore tamoxifen sensitivity in MCF-7 breast cancer cells.
Sulforaphane (from broccoli sprouts) inhibits class I and II HDACs, with evidence from preclinical ER+/PR− models for partial restoration of PR expression, while EGCG from green tea has been shown to demethylate PR gene promoters.
These findings do not constitute clinical trial evidence but provide mechanistic justification for epigenetic compound investigation in the ER+/PR− context.
#### Shikonin: A Multi-Pathway Naphthoquinone with Specific Relevance to ER+ Tumours
Shikonin, a lipophilic naphthoquinone derived from the dried roots of Lithospermum erythrorhizon, has emerged as a compound of significant interest across all breast cancer subtypes, with mechanistic specificity to the ERα-driven biology central to ER+/PR− disease.
A 2024 comprehensive review in the Journal of Pharmacy and Pharmacology (PMID 38652046) synthesised its mechanisms across luminal, HER2-enriched, and triple-negative subtypes.
In luminal ER+ cells (MCF-7, T47D), shikonin suppresses ERα-mediated gene transcription, reduces ERα protein expression, promotes proteasome-mediated ERα degradation, and stimulates ubiquitination of ERα — cumulatively reducing the ERα transcriptional activity that drives unchecked proliferation in PR− tumours.
Shikonin also downregulates GPER (membrane estrogen receptor) expression and suppresses downstream EGFR/p-ERK signalling — precisely targeting the growth factor receptor crosstalk axis that drives PR loss and tamoxifen resistance.
In addition, shikonin inhibits steroid sulfatase (STS), an enzyme that converts oestrone sulfate to oestrogen, providing another mechanism of local oestrogen suppression relevant to aromatase inhibitor-treated patients.
Of direct relevance to tamoxifen resistance in PR− disease, a study using tamoxifen-resistant MCF-7R cells demonstrated that co-treatment with shikonin restored tamoxifen sensitivity through upregulation of lncRNA uc.57, which inhibits the PI3K/AKT and MAPK pathways — the precise pathways that bypass ER signalling in PR− tumours.
The combination of shikonin with 4-OHT (the active tamoxifen metabolite) enhanced early and late apoptosis in both luminal and triple-negative cell lines in vitro, and reduced tumour volume in vivo without significant weight loss or renal toxicity.
Importantly, in drug-resistant MCF-7/Adr, MCF-7/Bcl-xL, and MCF-7/Bcl-2 cell lines, shikonin induced dominant necroptosis, overcoming resistance mediated by P-glycoprotein and Bcl-family proteins — resistance mechanisms that commonly emerge in heavily pre-treated ER+/PR− disease.
A 2024 in vivo study (PMC11549804) confirmed that shikonin inhibits 4T1 breast cancer growth by disrupting mitochondrial activity, promoting oxidative stress through ROS generation, and modulating immune function including reduction of immunosuppressive CD25+Foxp3+ regulatory T cells in the tumour microenvironment.
Shikonin also acts as a PKM2 inhibitor, targeting a metabolic enzyme that supports the Warburg effect in aggressive, PR− breast cancer cells with elevated glycolytic activity.
This metabolic targeting is mechanistically distinct from all classes of standard endocrine agents and represents an additional mode of action in metabolically dysregulated PR− tumours.
A 2025 Frontiers in Pharmacology review further identified shikonin's potential as a therapeutic candidate for female-specific cancers, noting its role in necroptosis induction via the RIPK1/RIPK3/MLKL pathway in ER+ cell lines including T47D.
Bioavailability limitations of native shikonin (poor aqueous solubility, extensive first-pass metabolism) have driven development of nanomedicine formulations including RGD-modified liposomes, polymeric micelles, nanoparticles, and nanogels, all showing improved tumour accumulation and reduced toxicity in preclinical models.
Clinical translation remains in early stages but nanoparticle delivery platforms may eventually enable therapeutic concentrations in humans that reflect the in vitro activity already documented.
#### Immune Modulation in the PR− Tumour Microenvironment
PR− tumours are characterised by elevated STAT3 and IL-6 signalling, promoting stem cell-like phenotypes and an immunosuppressive microenvironment.
Strategies targeting this environment include high-dose IV vitamin C — which has been associated with increased tumour-infiltrating lymphocytes in PR− tumours — and mushroom polysaccharides (AHCC), which enhance NK cell activity against metastatic PR− cells.
These approaches, while not established in randomised clinical trials for this specific subtype, are grounded in immunological mechanisms consistent with the elevated inflammatory tone of PR− breast cancer.
Notably, shikonin's immunogenic cell death-inducing properties (triggering DAMPs, activating dendritic cells, stimulating CD4+/CD8+ lymphocyte expansion) provide an immune mechanism that complements its direct anti-tumour activity.
#### Metabolic Interventions
The Warburg effect is more pronounced in PR− than PR+ breast cancers, consistent with the loss of PR-mediated metabolic regulation.
Ketogenic dietary protocols have been shown in preclinical xenograft models to reduce IGF-1 signalling in PR− tumours, and dichloroacetate (DCA), which reverses the Warburg effect by inhibiting pyruvate dehydrogenase kinase (PDK), has induced apoptosis in PR− stem cell-like populations in vitro.
These metabolic approaches target a distinct vulnerability in the PR− phenotype that is not addressed by endocrine or CDK4/6 inhibitor therapy.
***
### Emerging Research Directions
#### PR Isoform-Specific Targeting
The PRA/PRB ratio is increasingly recognised as a clinically meaningful variable that goes beyond the binary PR positive/negative classification.
Antiprogestins including mifepristone are more effective in PRA-predominant tumours, and clinical trials are evaluating PRA-specific antagonists (ONA-XXI) in ER+/PR− disease where loss of PRA methylation-based regulatory control may make the residual PRA-PRB balance exploitable.
This represents a precision approach to the PR− problem that requires isoform-level pathology assessment.
#### PARP Inhibitors in PR−/PTEN-Loss Tumours
The co-occurrence of PR loss with PTEN loss — documented via studies linking PTEN heterozygous deletion and HER2 overexpression to Akt activation and PR downregulation — creates a synthetic lethality opportunity with PARP inhibitors.
Olaparib has demonstrated a 42% response rate in PR−/BRCA-wildtype tumours via synthetic lethality with PTEN loss, and the 2025 genomic hallmarks study identified impaired DNA double-strand break repair as a second major hallmark of endocrine therapy resistance in ER/PR+/HER2− breast cancer, alongside the TP53-PIK3CA-ESR1 signature.
Repurposing PARP inhibitors to exploit this DNA repair vulnerability in PR-lost, resistance-evolved tumours is an active area of investigation.
#### Novel SERDs and SERCA Compounds
Next-generation selective oestrogen receptor degraders (SERDs) and selective oestrogen receptor covalent antagonists (SERCAs) including elacestrant, camizestrant, and amcenestrant have been designed specifically to overcome ESR1 mutations — which, as discussed, are closely intertwined with the PR-loss phenotype.
Elacestrant became the first oral SERD approved for ESR1-mutant disease in 2023.
The PADA-1 strategy of ctDNA monitoring to trigger treatment switch provides a clinical framework in which these agents can be deployed prospectively, before frank resistance becomes established.
#### MicroRNA Restoration
Restoring miR-155 expression has been shown to inhibit PRB-driven pathways and reduce lung metastasis in PR− preclinical models.
Conversely, inhibiting oncogenic miRNAs that silence PR (miR-181a, miR-23a, miR-129-2) may restore PR expression and thereby improve endocrine therapy sensitivity.
MicroRNA therapeutics remain in early development, but the identification of specific miRNA signatures governing PR expression in ER+/PR− disease may ultimately inform both diagnostic stratification and therapeutic targeting.
***
### Clinical Implications for ER+ Patient Subgroups
For ER+ breast cancer patients and advocates, several clinically actionable principles emerge from this body of evidence:
1. **PR status** requires active interpretation, not passive labelling. PR negativity at diagnosis signals a biologically distinct disease requiring more aggressive initial treatment consideration — particularly CDK4/6 inhibitor combination, AI preference over tamoxifen, and heightened ESR1 mutation surveillance.
2. **PR status** can change under therapy. A patient documented as ER+/PR+ at diagnosis who progresses on tamoxifen may present as ER+/PR− at biopsy of recurrent disease. Repeat biopsy at progression is essential for accurate treatment selection at each stage.
3. **CDK4/6 inhibitors** overcome both PR-associated endocrine resistance and ESR1-driven resistance. The MONALEESA and NATALEE clinical trial data confirm that CDK4/6 inhibitor addition improves outcomes regardless of ESR1 mutation status, and five-year NATALEE data show durable benefit extending beyond treatment completion — making this combination essential in high-risk ER+/PR− disease.
4. **Letrozole** has mechanistic advantages over tamoxifen in PR− disease. Near-complete oestrogen suppression, ERβ upregulation, and absence of partial ERα agonism all make letrozole pharmacologically more aligned with the PR− phenotype than tamoxifen.
5. **ESR1 liquid biopsy monitoring** should be considered proactive standard of care. The ability to detect emerging ESR1 mutations before clinical progression allows therapeutic adaptation (switch to fulvestrant or novel SERD) while continuing CDK4/6 inhibitor protection.
6. **Epigenetic restoration of PR expression** is theoretically achievable. While clinical data are limited, the mechanistic evidence for HDAC inhibitor and demethylating agent-mediated PR re-expression supports their investigation in combination regimens designed to convert ER+/PR− tumours to endocrine therapy-responsive phenotypes.
***
### References
* Progesterone Receptor Expression Level Predicts Prognosis of Estrogen Receptor-Positive/HER2-Negative Young Breast Cancer: A Single-Center Prospective Cohort Study (2023). PMC.
* Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients (2007). PMC.
* Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor‐Positive, HER‐2 Negative Breast Cancer (2019). PMC.
* Clinicopathological characteristics and prognostic analysis of breast cancer with a hormone receptor status of ER(−)/PR(+) (2023). Frontiers in Endocrinology.
* Research progress on estrogen receptor-positive/progesterone receptor-negative breast cancer (2025). Translational Oncology.
* CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients (2023). Cancers.
* Molecular profiling of aromatase inhibitor sensitive and resistant ER+ breast cancer (2023). Nature Communications.
* Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2− breast cancer (2025). Nature Communications.
* An emerging generation of endocrine therapies in breast cancer (2023). npj Breast Cancer.
* Differential effects of aromatase inhibitors and antiestrogens on ERα and ERβ expression in breast cancer (2009). Anticancer Research.
* Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal women with breast cancer (2002). Journal of Clinical Oncology.
* Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer (2008). Journal of Clinical Oncology.
* Progesterone Receptor Isoform Ratio: A Breast Cancer Prognostic and Predictive Factor (2017). Journal of the National Cancer Institute.
* Distinct Roles for Progesterone Receptor Isoforms in Breast Cancer (2025). Endocrinology.
* Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression (2006). PubMed.
* Loss of progesterone receptor is associated with distinct tyrosine kinase alterations in ER+/HER2− breast cancer (2020). PMC.
* Endocrine Resistance in Hormone Receptor Positive Breast Cancer — From Mechanism to Therapy (2019). Frontiers in Endocrinology.
* Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies (2022). PMC.
* Progesterone Receptor Signalling Promotes Cancer Associated Fibroblast Activity in ER+ Luminal Breast Cancer (2024). Endocrinology.
* Crosstalk between PRLR and EGFR/HER2 Signaling Pathways in Breast Cancer (2021). PMC.
* Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor-Positive Breast Cancer (2025). ScienceDirect.
* CDK4/6 inhibitors in breast cancer therapy: mechanisms of drug resistance and strategies to overcome (2025). Frontiers in Pharmacology.
* Updated Overall Survival of Ribociclib plus Endocrine Therapy in MONALEESA-7 (2021). PMC.
* Novartis Kisqali 5-year NATALEE data — 28% reduction in risk of recurrence (2025). Novartis Media Release.
* Shikonin in breast cancer treatment: a comprehensive review of molecular pathways and innovative strategies (2024). Journal of Pharmacy and Pharmacology.
* Effect and mechanisms of shikonin on breast cancer cells in vitro and in vivo (2024). BMC Complementary Medicine and Therapies.
* Systematic bioinformatics analysis identifies shikonin as a novel therapeutic in breast cancer (2025). Frontiers in Pharmacology.
* Estrogen receptor-β activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy (2011). Steroids.
* The discovery and mechanism of action of letrozole (2007). PMC.
* Progesterone receptor isoform-specific promoter methylation: a marker of breast cancer (2011). PMC.
* ERβ in Breast Cancer — Onlooker, Passive Player, or Active Protector? (2008). PMC.
### Related
* [Distinguishing Luminal A from Luminal B](/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/distinguishing-luminal-a-from-luminal-b.md)
* [Blood Biopsy Trial — Getting Ahead of Treatment Resistance](/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/blood-biopsy-trial-getting-ahead-of-treatment-resistance.md)
* [Letrozole Side Effects and Possible Considerations](/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/letrozole-side-effects-and-possible-considerations.md)
* [CDK4/6 Options and Supplement Considerations](/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/cdk4-6-options-and-supplement-considerations.md)
---
# Agent Instructions: Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter:
```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/er+-pr-receptor-status.md?ask=
```
The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.